Sanofi Ventures raises $625M for biotech innovation

We’re proud to share two major announcements. Immuto Scientific closed a new $8M financing round and launched a drug discovery collaboration with Daiichi Sankyo US to identify novel cancer-specific targets and develop new antibody-based therapies. The greatest challenge in drug discovery today is not a lack of modalities — it’s the shortage of truly novel, disease-specific targets. At Immuto Scientific, we are redefining target discovery with our AI-enabled structural surfaceomics platform, revealing cell-surface protein conformations invisible to conventional omics tools. These hidden structures open new therapeutic opportunities with exceptional precision and selectivity. With this new investment and alongside our partners, we’re propelling our internal oncology pipeline toward IND-enabling studies, expanding into immunology and inflammation and advancing our industry leading AI platform- built to unlock unprecedented insights into disease biology and reveal entirely new therapeutic targets. The financing was led by DYDX Capital with participation from new investors Gravity Fund and NVNG Investment Advisors, LLC and existing investors Great Oaks Venture Capital, WARF Ventures, among others. Read the release for more: https://lnkd.in/guKzprnN Learn more at www.immutotherapeutics.com #drugdiscovery #oncology #cancer #structuralsurfaceomics #targetdiscovery #ADCs #biotech #financing

Proud to announce two major milestones for Immuto Scientific! We’ve closed an oversubscribed $8M financing round and launched our first discovery collaboration with Daiichi Sankyo US to uncover novel surface targets in cancer. We’re pleased to welcome new investors DYDX Capital, Gravity Fund, and NVNG Investment Advisors, LLC to the team, and to deepen our partnership with the investors who have supported us from day one, including Great Oaks Venture Capital, Wisconsin Alumni Research Foundation (WARF) Ventures, and others. Over the last few years, our team has been working relentlessly to build cutting-edge platforms with unparalleled capabilities to uncover novel, disease-specific targets that were hiding in plain sight. That vision is now a reality. By revealing the hidden conformations of cell-surface proteins that define disease at a structural level, we’re expanding the target universe and opening doors to therapies with unprecedented precision and selectivity. We are advancing an internal pipeline of programs with first-in-class potential and collaborating with Daiichi Sankyo to expand into new areas. Together, we are illuminating what the field has long overlooked: the structural fingerprint of disease.   Thank you to our investors, our partners, and the Immuto team for making this vision real.

"Immuto Scientific creates and leverages data that no other group in the world has.” - Spencer M. of DYDX Capital Excited for this $8M round... but also the partnership with Daiichi Sankyo US, to discover new drug targets in solid tumors using its proprietary structural surfaceomics platform and to develop antibodies against these targets. In this funding round, Tundra Angels is thrilled to join up with Spencer M. of DYDX Capital, Adam G. of Gravity Fund, and continue the journey with Greg Keenan, Joshua J. Carson, Katie Rice, and Mike Partsch at Wisconsin Alumni Research Foundation (WARF) Ventures, Great Oaks Venture Capital, Brad Bodden Wisconsin Investment Partners, among others. Collectively, we're excited to be part of unlocking the new era of data‑driven drug discovery. 🚀

I am thrilled to announce several critical milestones for Immuto: an oversubscribed, $8M fundraise, the realization of our target discovery and drug development platform, and an exciting collaboration with our valued colleagues at Daiichi Sankyo US. We're pleased to have this announcement covered by Boston Business Journal (https://lnkd.in/eCewZ-DP) and FirstWord Pharma (https://lnkd.in/eMENUXCz) Stepping into this next chapter for Immuto Scientific is about doing drug discovery differently. Armed with support from our visionary investors, we are leveraging our AI-enabled structural surfaceomics platform to find the hidden conformations of surface proteins that exist only in disease. By targeting these unique structures, we can develop therapies with unmatched precision. Additionally, working alongside our colleagues at Daiichi Sankyo US, we’re building strong momentum for what’s ahead. So proud to be a member of this team and I’m so excited for everyone to see what we do next.

What if targets were defined by structure, not just expression? That’s the door we’re opening: disease-specific conformations that legacy target ID couldn’t detect. At Immuto Scientific, we’re building a next-gen protein-folding AI grounded in high-resolution structural proteomics to infer in-cell conformational states. It powers our structural surfaceomics platform and enables rational design of antibodies against structural, disease-specific epitopes—targets that simply weren’t visible before. We’re now putting that engine to work with Daiichi Sankyo US in a discovery collaboration to identify cancer-specific surface targets and develop antibodies against them. Grateful to our team and investors for making this possible. #AIinBiotech #ProteinFolding #AntibodyDiscovery #DrugDiscovery

Exciting news from the team at Immuto Scientific! We just closed an $8M financing round and launched a drug discovery collaboration with Daiichi Sankyo US. At Immuto, we’re tackling one of the toughest challenges in drug discovery — finding truly novel, disease-specific targets. Using our AI-enabled structural surfaceomics platform, we uncover hidden protein structures that open the door to new therapies with greater precision and selectivity. With this support, we’re advancing our oncology pipeline, expanding into immunology and inflammation, and most importantly — working to bring life-changing therapies to patients. An exciting future path lies ahead as we push the boundaries of what’s possible in target discovery and drug development. Grateful to our amazing team, partners, and investors who share this vision. #DrugDiscovery #Oncology #Biotech #Immunology #AIinBiotech #ADCs #CancerResearch #Innovation #Startups #LifeChangingTherapies

🚀 At Columbus Venture Partners we are proud to share great news from our portfolio: ARTHEx Biotech has successfully closed an upsized Series B round of $87M. This financing, led by Bpifrance and joined by all existing investors, will accelerate the global clinical development of ATX-01, a first-in-class RNA therapeutic for Myotonic Dystrophy Type 1 (DM1), and expand the company’s pipeline into other diseases with high unmet needs. At #Columbus, we continue to back pioneering science that creates impact for patients and delivers strong value for investors 🧬✨ #Biotech #VentureCapital #RNATherapeutics #DM1 #InvestingInHealth https://lnkd.in/dtxmsYYs

💰 Biotech's Top Investments This Week! 🚀 🇺🇸 Ovid Therapeutics | $175 million PIPE | small molecules | lead asset for treatment-resistant seizures 🇺🇸 Jade Biosciences | $135 million private placement | autoimmune disease therapies | phase 1 in immunoglobulin A nephropathy (IgAN) 🇮🇹 NanoPhoria | €83.5 million ($97 million) series A | peptides | lead asset for heart failure 🇺🇸 TORL Biotherapeutics LLC | $96 million series C | antibody-based immunotherapies | phase 2 in ovarian cancer 🇬🇧 Trogenix | $95 million series A | cancer therapies | lead asset for glioblastoma 🇺🇸 Cartography Biosciences | $67 million series B | bispecific and multi-specific antibodies | lead asset for colorectal cancer     🇮🇪 Aerska | $21 million seed | RNA medicines for neurological diseases 🇺🇸 Cirrus Therapeutics | $11 million seed | gene and cell therapies | preclinical in dry AMD 🇺🇸 Artelo Biosciences, Inc. | $2 million public offering | cancer, pain, dermatologic, and neurological condition treatments | phase 2 in cancer-related anorexia Subscribe to our newsletter for more fundraising updates! 🔗 https://lnkd.in/dsgz62YY #fundraising #funding #biotech #venturecapital #fundinground #biotechstartup #seriesa #seriesb #seriesc #investors #IPO #seedfunding

Investor Matt Bettonville joins us to explore a bold new frontier in cancer care—where software can outperform pharmaceuticals. Alongside Reed Jobs at Yosemite, Matt is backing digital health tools that have shown survival outcomes rivaling, and in some cases surpassing, traditional cancer drugs. Yosemite’s hybrid model of venture investing and grantmaking is designed to fast-track innovation and ensure it reaches the people who need it most. We dive into:  📊 How digital interventions are reshaping survival curves  💸 The economics of drug development vs. digital therapeutics  🧬 Synthetic control arms and the future of clinical trials  🔍 Early detection tech—from liquid biopsies to at-home diagnostics  🌐 Why global leadership in healthcare innovation is up for grabs Listen here:  Apple: https://lnkd.in/gRkQM9aJ Spotify: https://lnkd.in/gy-C_fBD #DigitalTherapeutics #CancerInnovation #YosemiteFund #NextGenCures #EndCancer #HealthTech #TheHeartOfHealthcare

Digital health is a core part of Yosemite’s investment strategy to foster transformational change across oncology and the medical system. Yosemite’s @Matt Bettonville and @Reed Jobs joined the Heart of Healthcare podcast to talk about Yosemite’s work in the space and touched on a key moment that guided their philosophy of supporting wide-ranging digital health interventions.